Is TEE the key for novel antibiotics?
Research suggests a Transferable Exclusivity Extension (TEE) system is “the only existing option capable of incentivising antibiotic R&D in a sustainable manner” for Europe.
According to a new report, implementing a Transferable Exclusivity Extension (TEE) system could solve the “broken economic model” for researching and developing new antibiotics in Europe.
As the threat of antimicrobial resistance (AMR), sometimes called the hidden or silent pandemic, grows, new and novel antibiotics are needed to combat infections becoming more resistant to current treatments.
Research published by Charles River Associates for The European Federation of Pharmaceutical Industries and Associations (EFPIA) suggests adopting a TEE proposal is the most credible and workable solution for driving antibiotic research in Europe. The authors suggest under such a system, two new antibiotics a year could be brought to patients over the next decade, preventing some of the 400,000 deaths associated with AMR every year in the EU.
Display your AMR Technology, Product and Service
Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.